Intellia Therapeutics (NTLA) Non-Current Deferred Tax Liability (2022 - 2025)

Intellia Therapeutics (NTLA) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $517.2 million in Q4 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 861.34% year-over-year to $517.2 million in Q4 2025; TTM through Dec 2025 was $517.2 million, a 861.34% increase from a year earlier, with the FY2025 full-year figure at $517.2 million, up 861.34% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2025 stood at $517.2 million, up from $53.8 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for NTLA reached as high as $517.2 million in Q4 2025 and fell as low as $53.8 million in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $314.8 million across 4 years, with a median of $344.2 million in 2022.
• Across the five-year window, Non-Current Deferred Tax Liability slumped 85.29% in 2024 and soared 861.34% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $322.6 million in 2022, then gained by 13.39% to $365.8 million in 2023, then slumped by 85.29% to $53.8 million in 2024, then surged by 861.34% to $517.2 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $517.2 million in Q4 2025, $53.8 million in Q4 2024, and $365.8 million in Q4 2023.